Renal Survival and Validation of Novel International Immunoglobulin a Nephropathy Prediction Tool in Latvian Population: Preliminary Data-Reference-Cited by-同舟云学术

Renal Survival and Validation of Novel International Immunoglobulin a Nephropathy Prediction Tool in Latvian Population: Preliminary Data

Published:2021-10-01 Issue:5 Volume:75 Page:379-386
ISSN:2255-890X
Container-title:Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
language:en
Short-container-title:

Author:

Saulīte Anna Jana¹²,Popova Anna¹²³,Erts Renārs³,Rācenis Kārlis¹²,Kučāne Linda⁴,Pētersons Aivars¹²,Laurinavičius Arvydas⁵,Čerņevskis Harijs¹²,Kuzema Viktorija¹²

Affiliation:

1. Centre of Nephrology , Pauls Stradiņš Clinical University Hospital , 13 Pilsoņu Str., LV-1002 , Rīga , Latvia

2. Faculty of Medicine , Rīga Stradiņš University , 16 Dzirciema Str., LV-1007 , Rīga , Latvia

3. Faculty of Medicine , University of Latvia , 3 Jelgavas Str., LV-1004 , Rīga Latvia

4. Medicin-och Geriatrikkliniken , Värnamo sjukhus, 33815 Värnamo , Sweden

5. Faculty of Medicine , Vilnius University , 21 M. K. Čiurlionio Str., LT-03101 , Vilnius , Lithuania

Abstract

Abstract The aim of the study was to determine kidney survival and validate the novel international immunoglobulin A nephropathy (IgAN) prediction tool (PT) in the Latvian population. Adults with morphologically confirmed IgAN were included. Kidney survival was analysed with the Kaplan–Meier method. PT-assigned risk was compared with calculated risk by the Cox regression model. The Kaplan–Meier analysis included 95 patients. The five-year kidney survival Q3 was 24 months. Women had longer median kidney-survival time (> 60 months) than men (58 months). Median kidney survival in participants with MEST T0 was longer than 60 months; T1 and T2 were 40 and 18 months, respectively. Median kidney survival in participants with diastolic blood pressure (DBP) < 99 mmHg was longer than 60 months, whereas in patients with DBP 100–109 and 110 mmHg, it was 40 and 24 months, respectively. Cox regression analysis included 68 patients. A moderate degree of correlation was found between predicted and observed five-year risk (p = 0.001). Gender, tubular atrophy/interstitial fibrosis, DBP are significant factors affecting kidney survival. Since there was statistically significant correlation and reliability between PT and follow-up analysis data, we conclude that PT could be applied for use in the Latvian population.

Publisher

Walter de Gruyter GmbH

Link

https://www.sciendo.com/pdf/10.2478/prolas-2021-0055

Reference28 articles.

1. Barbour, S. J., Coppo, R., Zhang, H., Liu, Z. H., Suzuki, Y., Matsuzaki, K., Katafuchi, R., Er, L., Espino-Hernandez, G., Kim, S. J., Reich, H. N., Feehally, J., Cattran, D. C. (2019). International IgA nephropathy network. Evaluating a new International Risk-Prediction Tool in IgA Nephropathy. JAMA Intern Med., 179 (7), 942–952. Erratum in: JAMA Intern Med., 2019, 179 (7), 1007.

2. Barbour, S. J., Espino-Hernandez, G., Reich, H. N., Coppo, R., Roberts, I. S., Feehally, J., Herzenberg, A. M., Cattran, D. C. (2016). The MEST score provides earlier risk prediction in lgA nephropathy. Kidney Int., 89 (1),167–175.10.1038/ki.2015.322

3. Chang, A., Laszik, Z. (2018). Kidney and its collecting system. In: Vinay, K., Abbas, A. K., Aster, J. C. (eds.). Robbins Basic Pathology. Elsevier, Philadelphia, Chapter 14, pp. 549–581.

4. Chen, D., Liu, J., Duan, S., Chen, P., Tang, L., Zhang, L., Feng, Z., Cai, G., Wu, J., Chen, X. (2018). Clinicopathological features to predict Pprogression of IgA nephropathy with mild proteinuria. Kidney Blood Press Res., 43 (2), 318–328.10.1159/000487901

5. Cheng, J., Zhang, W., Zhang, X. H., He, Q., Tao, X. J., Chen, J. H. (2009). ACEI/ARB therapy for IgA nephropathy: A meta-analysis of randomised controlled trials. Int. J. Clin. Pract., 63 (6), 880–888.10.1111/j.1742-1241.2009.02038.x